Analystreport

Vistagen Therapeutics Inc (NASDAQ: VTGN) was downgraded by analysts at Chardan Capital to a "hold" rating. They now have a $0.70 price target on the stock.

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com